Abstract:While protein coronas (PCs) are an important barrier in the clinical application of nanomedicines, the specific effects of PCs on nanoparticles (NPs) in vivo are unclear. Herein, we demonstrated that PCs from clinical sources greatly influenced the active targeting capacities of transferrin-modified NPs (Tf-NPs). Compared to PCs from healthy volunteers, PCs from the plasma of patients with nonsmall cell lung cancer (NSCLC) decreased the A549 uptake of Tf-NPs to a greater degree. The PC proteome revealed that this difference may be mediated by certain proteins in plasma. To attenuate the negative influence of PCs from patients, precoating Tf-NPs with PCs derived from healthy mice significantly enhanced active targeting capacities. Paclitaxel-loaded Tf-NPs with PCs derived from healthy mice showed the strongest antitumor effects in mice with NSCLC. This work illustrates the influence of PCs of ligand-modified NPs in clinical practice and proposes the use of corona-enabled active targeting for precision nanomedicine.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.nanolett.0c03982?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.nanolett.0c03982</a>.Details related to materials and methods; characterization of particle size and zeta (ζ) potential of bare NPs and NPs with PC (Table S1); the amount of protein adsorbed on NPs (Table S2); the most abundant proteins (top 30) identified in the PC of NPs from human sources (Table S3); the most abundant proteins (top 30) identified in the PC of NPs from murine sources (Table S4); microscopic observation of coumarin+ A549 cells (Figures S1 and S3); normalized fluorescence intensity in A549 cells (Figures S2 and S4); schematic description of the experimental design for studies of in vivo mouse PC formation (Figure S5); the intensity diameter distribution of NPs with/without in vivo mouse-derived PC (Figure S6); TEM images of NPs with/without in vivo mouse-derived PC (Figure S7); microscopy observation of coumarin+ LL/2 cells (Figures S8 and S10); the normalized fluorescence intensity in LL/2 cells (Figures S9 and S11); fluorescence intensity in organs and tumor 24 h post-injection (Figure S12); tumor size in all mouse groups (Figure S13); coomassie brilliant blue-stained SDS-PAGE gel of PCs associated with NPs (Figure S14); classification of PCs according to physiological function (Figure S15); Venn diagrams depicting the number of unique proteins identified in the in vitro-formed coronas and their respective overlap (Figure S16); Venn diagrams depicting the number of unique proteins identified in the in vivo-formed coronas and their respective overlap (Figure S17); and evaluation of NP safety and IgE concentrations in serum from all murine groups (Figure S18) (<a class="ext-link" href="/doi/suppl/10.1021/acs.nanolett.0c03982/suppl_file/nl0c03982_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Synthetic Nanocapsules with Tailored Surface Chemistry for Lung‐Specific Protein Delivery and Cancer Immunotherapy

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

Pulmonary Delivery of Immune Checkpoint Inhibitors Using a Responsive Polyethylene Glycol Nanogel for Treating Lung Metastasis

Lung-specific supramolecular nanoparticles for efficient delivery of therapeutic proteins and genome editing nucleases

Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.

Bioresponsive Chimaeric Nanopolymersomes Enable Targeted and Efficacious Protein Therapy for Human Lung Cancers in Vivo

Biodegradable Silica Nanocapsules Enable Efficient Nuclear-Targeted Delivery of Native Proteins for Cancer Therapy.

Redox-Responsive Molecularly Imprinted Nanoparticles for Targeted Intracellular Delivery of Protein Toward Cancer Therapy.

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

Cell membrane coated nanoparticles as a biomimetic drug delivery platform for enhancing cancer immunotherapy

Nanomicelle-Microsphere Composite as a Drug Carrier to Improve Lung-Targeting Specificity for Lung Cancer

Nanoantagonists with Nanophase-Segregated Surfaces for Improved Cancer Immunotherapy.

Nanoenabled IL-15 Superagonist via Conditionally Stabilized Protein-Protein Interactions Eradicates Solid Tumors by Precise Immunomodulation

Gold Nanoparticle-Guarded Large-Pore Mesoporous Silica Nanocomposites for Delivery and Controlled Release of Cytochrome C.

Dynamically Crosslinked Nanocapsules for the Efficient and Serum-Resistant Cytosolic Protein Delivery

Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy

Hierarchical Nanoassemblies-Assisted Combinational Delivery of Cytotoxic Protein and Antibiotic for Effective Cancer Treatment.

Targeted Lung Cancer Therapy: Preparation and Optimization of Transferrin-Decorated Nanostructured Lipid Carriers As Novel Nanomedicine for Co-Delivery of Anticancer Drugs and DNA

Nanocapsules: Macrophage Cell Membrane Camouflaged Mesoporous Silica Nanocapsules for In Vivo Cancer Therapy (Adv. Healthcare Mater. 11/2015)

Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles

Genetically Engineered Plasma Membrane Nanovesicles for Cancer-Targeted Nanotheranostics